The SAR of a series of 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols as monoamine reuptake inhibitors, with a goal to improve both potency toward inhibiting the norepinephrine transporter and selectivity over the serotonin transporter, is reported. The effect of specific substitution on both the 3-phenyl group and the indole moiety were explored. This study led to the discovery of compound 20 which inhibited the norepinephrine transporter with an IC50 value of 4 nM while exhibiting 86-fold selectivity over the serotonin transporter.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2009.07.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of YOXINTINE for depression: A double-blinded, randomized, placebo-controlled, phase 2 clinical trial.
Phytomedicine
November 2024
Mental Health Center, West China Hospital, Sichuan University, Chengdu 610041, PR China. Electronic address:
Background: YOXINTINE contains >98 % of 20(S)-protopanaxadial (PPD), a metabolic product of ginsenosides with pre-clinical neuroprotective activity. Animal experiments and previous studies have shown that PPD has good antidepressant effect and safety.
Purpose: To evaluate YOXINTINE in treating depression compared with a placebo in Chinese patients.
Brazilian Psychiatric Association guidelines for the treatment of Social Anxiety Disorder.
Braz J Psychiatry
November 2024
Mental Health Department, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.
Article Synopsis
- Social anxiety disorder (SAD) is a common yet often overlooked condition that can severely impact various aspects of a person's life, highlighting the need for tailored treatment guidelines, particularly in Brazil.
- A systematic review analyzed various treatment options for SAD, identifying selective serotonin reuptake inhibitors (SSRIs) as the preferred medication, with cognitive behavioral therapy (CBT) recognized as the top psychological intervention.
- The study emphasizes the importance of considering factors like access to treatments, adherence, response rates, and side effects in selecting the most effective SAD treatment for patients in Brazil.
Drug-Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database.
Pharmaceuticals (Basel)
September 2024
Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
As the most common psychiatric symptom, depression represents a subject of high interest for the medical community. : International guidelines consider selective serotonin reuptake inhibitors (SSRIs) the first-line treatment of depression. Although having better efficacy and tolerability in comparison to tricyclic antidepressants or monoamine oxidase inhibitors, the diversity and potential severity of adverse effects and interactions manifested by SSRIs, combined with the frequency of prescriptions, lead to the necessity of evaluating real-world data.
View Article and Find Full Text PDFFirst-in-human study of D6-[F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [F]FP-(+)-DTBZ (AV-133).
EJNMMI Radiopharm Chem
October 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Article Synopsis
- D6-[F]FP-(+)-DTBZ is a new imaging agent designed for PET scans that helps diagnose Parkinson's disease (PD) by tracking VMAT2 transporters in the brain.
- In a study, this radioligand demonstrated efficient production, high purity, and distinct uptake in brain regions associated with PD, showing a greater effectiveness compared to its non-deuterated counterpart.
- The findings suggest that D6-[F]FP-(+)-DTBZ could serve as a safer, more effective tool for monitoring VMAT2 levels in monoamine neurons, potentially improving PD diagnosis.
Pramipexole, a D3 receptor agonist, increases cortical gamma power and biochemical correlates of cortical excitation; implications for mood disorders.
Eur J Neurosci
November 2024
Interdisciplinary Program in Neuroscience, Georgetown University School of Medicine (GUMC), Washington, D.C., USA.
Major depressive disorder (MDD) has been associated with deficits in working memory as well as underlying gamma oscillation power. Consistent with this, overall reductions in cortical excitation have also been described with MDD. In previous work, we have demonstrated that the monoamine reuptake inhibitor venlafaxine increases gamma oscillation power in ex vivo hippocampal slices and that this is associated with concomitant increases in pyramidal arbour and reduced levels of plasticity-restricting perineuronal nets (PNNs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!